Shandong Bailong Chuangyuan Bio-Tech Toekomstige groei
Future criteriumcontroles 5/6
Shandong Bailong Chuangyuan Bio-Tech is forecast to grow earnings and revenue by 30.6% and 27.6% per annum respectively. EPS is expected to grow by 30.3% per annum. Return on equity is forecast to be 18.7% in 3 years.
Belangrijke informatie
30.6%
Groei van de winst
30.3%
Groei van de winst per aandeel
| Food winstgroei | 22.1% |
| Inkomstengroei | 27.6% |
| Toekomstig rendement op eigen vermogen | 18.7% |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 31 Oct 2024 |
Recente toekomstige groei-updates
Recent updates
Shandong Bailong Chuangyuan Bio-Tech Co., Ltd.'s (SHSE:605016) Intrinsic Value Is Potentially 78% Above Its Share Price
Oct 14
Many Still Looking Away From Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. (SHSE:605016)
Sep 29Here's Why Shandong Bailong Chuangyuan Bio-Tech (SHSE:605016) Has Caught The Eye Of Investors
Aug 23Returns On Capital At Shandong Bailong Chuangyuan Bio-Tech (SHSE:605016) Have Hit The Brakes
Jun 26Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. (SHSE:605016) Analysts Are More Bearish Than They Used To Be
May 06Concerns Surrounding Shandong Bailong Chuangyuan Bio-Tech's (SHSE:605016) Performance
May 03If EPS Growth Is Important To You, Shandong Bailong Chuangyuan Bio-Tech (SHSE:605016) Presents An Opportunity
Mar 27Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 1,952 | 470 | 290 | 406 | 3 |
| 12/31/2025 | 1,561 | 365 | 218 | 319 | 3 |
| 12/31/2024 | 1,197 | 271 | -169 | 73 | 3 |
| 9/30/2024 | 1,035 | 234 | -65 | 217 | N/A |
| 6/30/2024 | 987 | 221 | -44 | 191 | N/A |
| 3/31/2024 | 926 | 202 | -123 | 201 | N/A |
| 12/31/2023 | 868 | 193 | -117 | 195 | N/A |
| 9/30/2023 | 825 | 174 | -70 | 187 | N/A |
| 6/30/2023 | 742 | 163 | -29 | 191 | N/A |
| 3/31/2023 | 719 | 154 | -9 | 167 | N/A |
| 12/31/2022 | 722 | 151 | -26 | 150 | N/A |
| 9/30/2022 | 732 | 147 | -40 | 141 | N/A |
| 6/30/2022 | 739 | 131 | -13 | 143 | N/A |
| 3/31/2022 | 717 | 128 | -10 | 95 | N/A |
| 12/31/2021 | 653 | 104 | 40 | 96 | N/A |
| 9/30/2021 | 605 | 99 | -15 | 51 | N/A |
| 6/30/2021 | 566 | 97 | -33 | 32 | N/A |
| 3/31/2021 | 540 | 98 | 46 | 119 | N/A |
| 12/31/2020 | 500 | 96 | 37 | 122 | N/A |
| 9/30/2020 | 479 | 93 | 83 | 150 | N/A |
| 6/30/2020 | 464 | 92 | 75 | 138 | N/A |
| 3/31/2020 | 416 | 77 | -1 | 58 | N/A |
| 12/31/2019 | 421 | 83 | 8 | 64 | N/A |
| 12/31/2018 | 356 | 65 | 1 | 89 | N/A |
| 12/31/2017 | 311 | 64 | N/A | 113 | N/A |
| 12/31/2016 | 336 | 65 | N/A | 60 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: 605016's forecast earnings growth (30.6% per year) is above the savings rate (2.9%).
Winst versus markt: 605016's earnings (30.6% per year) are forecast to grow faster than the CN market (25.8% per year).
Hoge groeiwinsten: 605016's earnings are expected to grow significantly over the next 3 years.
Omzet versus markt: 605016's revenue (27.6% per year) is forecast to grow faster than the CN market (14% per year).
Hoge groei-inkomsten: 605016's revenue (27.6% per year) is forecast to grow faster than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: 605016's Return on Equity is forecast to be low in 3 years time (18.7%).